Phase 3 Ovarian Cancer Trial, Recruiting NCT06963268 Sponsor: Instituto de Investigacion Sanitaria La Fe Condition: Ovarian Cancer
Back to Ovarian Cancer

Phase 3 Ovarian Cancer Trial, Recruiting

NCT06963268
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are female and aged 18 or older at the time of joining the trial.
  • People who have been diagnosed with a malignant (cancerous) ovarian tumour confirmed by a tissue sample, where the cancer appears to be at an early stage (FIGO stage I or II), and who are scheduled for surgery to determine how far the cancer has spread.
  • People with a suspected early-stage malignant ovarian tumour (FIGO stage I or II) who will undergo exploratory surgery and a biopsy, and if that biopsy confirms cancer, will then proceed to staging surgery.
  • People who have signed a consent form agreeing to take part before any trial-related procedures begin.

Who may not be able to join:

  • People who have not given consent, or who have withdrawn their consent to participate.
  • People under 18 years of age at the time of joining.
  • People who have previously had vascular surgery on the aorta, the large vein running down the body (vena cava), or the blood vessels in the pelvis.
  • People who have previously had surgery on the lymph nodes in the pelvic or para-aortic region (the area alongside the large abdominal blood vessels).
  • People with a previous history of lymphoma (a type of cancer affecting the lymphatic system).
  • People who have previously had a tumour in the abdomen or pelvis.
  • People who have a known allergy to either Tc99 (a radioactive tracer) or ICG (a dye used in medical imaging).
  • People who are pregnant or breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: +34961246731

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Instituto de Investigacion Sanitaria La Fe
Registry
ClinicalTrials.gov
Start date
10 November 2025
Est. completion
1 June 2028

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Negative predictive value of the sentinel lymph node technique.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov